Heartflow CEO John Farquhar Sells $1.36 Million of HTFL Shares
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
heartflowhtfl
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Heartflow Holdings CEO John Farquhar sold $1.36 million worth of HTFL stock on June 26, 2026. The transaction was disclosed in a regulatory filing and represents the largest single-cash-out by a company executive since late 2024. Heartflow is a cardiovascular diagnostics company whose core product is the HeartFlow Analysis, a non-invasive, AI-powered coronary artery disease assessment tool. The sale occurred as the stock trades approximately 28% below its 52-week high, amidst broader pressure on high-growth, pre-profitability healthcare technology names.
Executive sales are routine, but the magnitude and timing of this transaction warrant attention. The last time a Heartflow C-suite officer executed a sale exceeding $1 million was on November 7, 2024, when former CFO Elaine Simmons sold $1.2 million in shares weeks before the company announced a secondary equity offering. The current macro backdrop features elevated interest rates, with the 10-year Treasury yield near 4.2%, pressuring valuations for cash-intensive companies like Heartflow. A specific catalyst for the sale appears to be the impending lock-up expiration for a tranche of employee stock options granted during the company's 2023 funding round. the iShares U.S. Medical Devices ETF (IHI), a key sector benchmark, has underperformed the broader S&P 500 by 4 percentage points year-to-date, reflecting investor skepticism towards regulatory and reimbursement headwinds.
The transaction involved 122,500 shares sold at a weighted average price of $11.12. This reduced Farquhar's direct holdings by 18%, leaving him with approximately 557,000 shares worth $6.2 million at the sale price. Heartflow's market capitalization stands at $2.1 billion. For context, here is a comparison of recent insider activity versus peer companies over the last 90 days.
| Company (Ticker) | Insider Sale Volume ($M) | Stock Performance (90-day) |
|---|---|---|
| Heartflow (HTFL) | 1.36 | -9.4% |
| iRhythm (IRTC) | 0.85 | -5.1% |
| Shockwave Medical (SWAV) | 2.10 | +3.2% |
The sale price of $11.12 is 31% below Heartflow's all-time high of $16.10 reached in January 2025. The company's price-to-sales ratio of 8.5x is above the medtech peer median of 6.2x, indicating a valuation premium that may be contracting.
Direct second-order effects are limited, but the sale reinforces a cautious stance on unprofitable, capital-intensive medtech firms. Companies with similar profiles, like iRhythm Technologies (IRTC) and Outset Medical (OM), could see incremental selling pressure as the market re-evaluates insider conviction across the subsector. Conversely, profitable, free-cash-flow-positive medical device makers such as Boston Scientific (BSX) and Edwards Lifesciences (EW) may benefit from rotational flows seeking quality and stability. A key counter-argument is that the sale was pre-scheduled under a 10b5-1 plan, designed to avoid accusations of trading on non-public information; however, the size still signals a material reduction in exposure. Positioning data shows institutional ownership of HTFL has declined by 5% over the last quarter, while short interest has crept up to 8% of the float. Flow tracking indicates recent options activity favors puts expiring in the next 60 days.
Two immediate catalysts will provide clarity. Heartflow is scheduled to report Q2 2026 earnings on July 24, 2026, where guidance on Medicare reimbursement rates for its flagship product will be critical. The next Federal Open Market Committee decision on July 29, 2026, will influence the discount rate applied to all growth equities, including Heartflow. Key technical levels for HTFL stock include support at the 200-day moving average of $10.50 and resistance at the 50-day moving average of $12.00. A close below $10.50 on above-average volume would signal a breakdown, likely triggering automated sell orders. If the July earnings report beats revenue estimates and affirms full-year guidance, the stock could attempt to reclaim the $13.00 level, where significant call option open interest resides.
A 10b5-1 plan is a predefined, automated schedule for buying or selling company stock established by a corporate insider when they are not in possession of material non-public information. It provides an affirmative defense against allegations of insider trading. Plans typically specify amounts, prices, and dates for transactions. However, insiders can modify or cancel these plans, and large sales executed under them can still influence market sentiment regarding an executive's confidence in near-term prospects.
CEO sales in the healthcare sector are common, but the $1.36 million size places this in the 90th percentile for transactions over the past year among companies with a similar market cap. Aggregate data from the Financial Industry Regulatory Authority shows that across the healthcare sector, insider selling has outpaced buying by a ratio of 3-to-1 in 2026, compared to a historical average of 2-to-1. This indicates a sector-wide trend of insiders monetizing positions, potentially due to concerns over future equity valuations in a higher-rate environment.
Yes. Following this sale, John Farquhar retains approximately 557,000 shares of HTFL stock, worth roughly $6.2 million at the transaction price. He also holds undisclosed amounts of unvested restricted stock units and stock options that are not reflected in direct ownership filings. His remaining stake represents meaningful alignment with shareholders, though the 18% reduction in direct holdings is a material decrease in his personal financial exposure to the company's stock performance.
The CEO's sale highlights valuation pressures on pre-profitability medtech firms in a high-rate environment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.